Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

8.260 +0.150 (+1.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine Mindmed Inc

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
Psychedelic Stock Gainers And Losers From January 3, 2023
Via Benzinga
Three Trends That May Shape the Psychedelics Industry Next Year
Via Investor Brand Network
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 2, 2023
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 29, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 28, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 27, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 26, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 30, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 116 companies set new 52-week lows. 
Via Benzinga
Largest Psychedelic Stocks -7.6% This Week; Now -21.7% This Month
Highlighting the performance of the six stocks in our Psychedelic Drug Stocks Index, which are researching the treatment of mental illnesses using 10 different psychedelic substances. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 23, 2022
Via Benzinga
Cybin, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 21, 2022
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 19, 2022
Via Benzinga
Major Psychedelic Drug Stocks Down Another 7% This Week; Now Down 54% YTD
The 6 largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances are down again this week. 
Via Talk Markets
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 14, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 13, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 9, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 7, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Another Financial Giant Will Stop Supporting Cannabis Stocks
Starting January 2023, Euroclear will reportedly no longer support trades of cannabis stocks. One of the world's largest financial clearing houses collaborating with the majority of the 50 largest... 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 12, 2022
Via Benzinga
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. 
Via Talk Markets
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.